Issues one press release announcing Bydureon approval and that's it. No follow-up press releases offering additional important material information or results to benefit shareholders, very little transparency and nothing to show that major changes are underway at the new Amylin . Bydureon may be approved and Lilly may be partially gone, but you would never know it had Amylin not told us so. Unfrotunatley the look and feel of the company is the still same today as it was before Bydureon's approval and Lilly divorce. Amylin needs to do something big to change the questionable perception the investment world has about the company. The company desperately needs a make over and a new look. We need proof that things are different, are changing from within and getting better, that is unless the goal is keep things steady while buyout negotiations are underway and until a deal is struck.
You don't have to believe in what I say and you should question not just my post, but every other post on this board. Just do your own DD. I share what I know and my own opinion base on what I know. I am sorry if some one out there cannot be benefit of the info and opinion I post. But thanks for the comment any way. Questioning is always a good thing. Just do me a favor, go to a pharmacy in the area, pretend like you are a patient and ask the pharmacist to look up the drug call Bydureon, how much it cost if you pay cash, how much it cost with your insurance, when can you get them? Depend on what whole sale supplier each pharmacy net work has, Mckesson, Cardinal ect. Each will be different. GLTA